
RealRate

PHARMACEUTICAL 2018

PROGENICS PHARMACEUTICALS INC Rank 142 of 349



RealRate

PHARMACEUTICAL 2018

PROGENICS PHARMACEUTICALS INC

Rank 142 of 349

The relative strengths and weaknesses of PROGENICS PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PROGENICS PHARMACEUTICALS INC compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 71% points. The greatest weakness of PROGENICS PHARMACEUTICALS INC is the variable Research and Development, reducing the Economic Capital Ratio by 42% points.

The company's Economic Capital Ratio, given in the ranking table, is -120%, being 157% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	96,870
Cost of Goods Sold	0
Intangible Assets	43,443
Liabilities, Current	15,359
Liabilities, Non-Current	48,770
Other Assets	1,522
Other Compr. Net Income	52
Other Expenses	-9,072
Other Liabilities	18,375
Other Net Income	-4,285
Property and Equipment	4,122
Research and Development	42,589
Revenues	11,698
Selling, General and Administrative Expense	24,909

Output Variable	Value in 1000 USD
Assets	145,957
Liabilities	82,504
Expenses	58,426
Stockholders Equity	63,453
Net Income	-51,013
Comprehensive Net Income	-50,987
Economic Capital Ratio	-120%